pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
GIP receptor · news · pharmadog
← back to GIP receptor
News · GIP receptor
23
stories
13h
Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
biospace
21h
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
fiercebiotech
4d
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
5d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
11d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
14d
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
biospace
19d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
20d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
20d
Amgen drops early-stage obesity drug, upping pressure on MariTide
fiercebiotech
20d
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
24d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
27d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
27d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 23, 26
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
